FY2026 EPS Estimates for MannKind Reduced by Leerink Partnrs

MannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for MannKind in a report released on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the year, down from their prior forecast of $0.23. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

Several other research firms have also recently weighed in on MNKD. Royal Bank of Canada upgraded MannKind from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $7.00 to $10.00 in a research report on Thursday. Oppenheimer raised their price target on shares of MannKind from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 28th. Leerink Partners started coverage on shares of MannKind in a report on Monday, September 9th. They issued an "outperform" rating and a $8.00 price objective for the company. StockNews.com cut shares of MannKind from a "buy" rating to a "hold" rating in a report on Saturday, December 7th. Finally, Wells Fargo & Company initiated coverage on shares of MannKind in a research report on Friday. They issued an "overweight" rating and a $9.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, MannKind has a consensus rating of "Buy" and an average target price of $8.88.

MannKind Stock Performance

NASDAQ:MNKD traded up $0.55 during mid-day trading on Friday, hitting $6.85. 7,214,138 shares of the stock were exchanged, compared to its average volume of 2,680,047. The firm's 50-day simple moving average is $6.75 and its 200 day simple moving average is $6.01. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 97.86 and a beta of 1.28. MannKind has a fifty-two week low of $3.17 and a fifty-two week high of $7.63.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its holdings in shares of MannKind by 401.8% during the third quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company's stock worth $1,060,000 after buying an additional 134,937 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in MannKind during the 3rd quarter worth $12,252,000. International Assets Investment Management LLC grew its position in MannKind by 511.6% during the 3rd quarter. International Assets Investment Management LLC now owns 88,689 shares of the biopharmaceutical company's stock worth $558,000 after acquiring an additional 74,189 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in MannKind by 37.1% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 3,304,085 shares of the biopharmaceutical company's stock worth $20,783,000 after purchasing an additional 894,486 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in MannKind in the third quarter valued at about $546,000. Institutional investors own 49.55% of the company's stock.

Insider Buying and Selling

In other MannKind news, Director Steven B. Binder sold 67,536 shares of the business's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.89, for a total transaction of $465,323.04. Following the completion of the transaction, the director now owns 1,075,026 shares of the company's stock, valued at approximately $7,406,929.14. The trade was a 5.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stuart A. Tross sold 55,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total transaction of $403,700.00. Following the completion of the sale, the insider now owns 967,191 shares in the company, valued at approximately $7,099,181.94. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 190,075 shares of company stock worth $1,325,587. Corporate insiders own 3.00% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.